TheraRadar

Amicus

Pre-Approval PRO BETA
24
Total Trials
12
Phase 3
6
Phase 2
4
Recruiting
254
Score

Pipeline by Phase

Phase 3
12
Phase 2
6
Phase 1
7

Therapeutic Focus

Fabry Disease Pompe Disease (Late-onset) Pompe Disease Type 1 Gaucher Disease Gaucher Disease

Clinical Trials (24)

NCT06904261 Phase 3 RECRUITING

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

Started: 1/8/2026

NCT04808505 Phase 3 RECRUITING

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Started: 7/18/2023

NCT04020055 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Started: 10/31/2022

NCT04138277 Phase 3 COMPLETED

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Started: 12/18/2019

NCT04049760 Phase 3 COMPLETED

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Started: 10/11/2019

NCT03911505 Phase 3 ACTIVE NOT RECRUITING

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Started: 2/13/2020

NCT03729362 Phase 3 COMPLETED

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

Started: 12/4/2018

NCT03500094 Phase 3 COMPLETED

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

Started: 9/27/2018

NCT02194985 Phase 3 COMPLETED

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

Started: 3/14/2015

NCT01218659 Phase 3 COMPLETED

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Started: 9/8/2011

NCT00925301 Phase 3 COMPLETED

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Started: 10/23/2009

NCT01458119 Phase 3 TERMINATED

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Started: 10/14/2011

NCT00688597 Phase 2 TERMINATED

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

Started: 12/8/2008

NCT01380743 Phase 2 COMPLETED

Drug-drug Interaction Study

Started: 10/31/2011

NCT01196871 Phase 2 COMPLETED

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Started: 2/2/2011

NCT00813865 Phase 2 COMPLETED

A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

Started: 5/11/2009

NCT00446550 Phase 2 COMPLETED

A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

Started: 6/11/2008

NCT02675465 Phase 1 COMPLETED

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Started: 4/1/2016

NCT01730469 Phase 1 COMPLETED

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Started: 8/1/2011

NCT02082327 Phase 1 COMPLETED

A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers

Started: 3/1/2014

NCT01489995 Phase 1 COMPLETED

Migalastat Food Effect Study

Started: 10/1/2011

NCT01853852 Phase 1 COMPLETED

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Started: 9/1/2011

NCT01730482 Phase 1 COMPLETED

A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)

Started: 8/1/2011

NCT00875160 Phase 1 TERMINATED

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Started: 4/1/2009

Drug Candidates

Migalastat HCl 20 mg migalastat HCl 150 mg AT2221 ATB200 Cipaglucosidase alfa Miglustat Cipaglucosidase Alfa Duvoglustat Alglucosidase Alfa duvoglustat
Activity Status: Active
Last Trial Started: 1/8/2026
Last Trial Ended: 12/31/2024
Trials (12 months): 1
Completed Trials: 17
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.